In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer

PURPOSE: The DNA Damage Immune Response (DDIR) assay was developed in breast cancer (BC) based on biology associated with deficiencies in homologous recombination and Fanconi Anemia (HR/FA) pathways. A positive DDIR call identifies patients likely to respond to platinum-based chemotherapies in breas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Malla, Sudhir B., Fisher, David J., Domingo, Enric V., Blake, Andrew, Hassanieh, Sylvana, Redmond, Keara L., Richman, Susan D., Youdell, Michael, Walker, Steven M., Logan, Gemma E., Chatzipli, Aikaterina, Amirkhah, Raheleh, Humphries, Matthew P., Craig, Stephanie G., McDermott, Ultan, Seymour, Matthew T., Morton, Dion G., Quirke, Philip, West, Nicholas P., Salto-Tellez, Manuel, Kennedy, Richard D., Johnston, Patrick G., Tomlinson, Ian, Koelzer, Viktor H., Campo, Letitia, Kaplan, Richard S., Longley, Daniel B., Lawler, Mark, Maughan, Timothy S., Brown, Louise C., Dunne, Philip D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614625/
https://ncbi.nlm.nih.gov/pubmed/33028592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados